| AUTOLUS THERAP. SP.ADR/1 |
| USA |
| Gesundheit |
| US05280R1005 / A2JNZJ |
| 6A3A (Frankfurt) / AUTL (NASDAQ) |
| FRA:6A3A, ETR:6A3A, 6A3A:GR, NASDAQ:AUTL |
| - |
| https://www.autolus.com/ |
|
Autolus Therapeutics plc ADR is a clinical-stage biopharmaceutical company focused on developing programmed T-cell therapies for cancer and autoimmune diseases. The company applies modular cell-engineering technologies to design autologous T-cell tre..
>Volltext.. |
| 329.7 Mio. EUR |
| 477.53 Mio. EUR |
| 105.26 Mio. EUR |
| -211.4 Mio. EUR |
| -250.88 Mio. EUR |
| -0.94 EUR |
| 330.17 Mio. EUR |
| 155.21 Mio. EUR |
| -201.95 Mio. EUR |
| 2.95 |
| 287.93% |
| -21.93% |
| - |
| - |
| - |
| - |
| AUTOLUS |
| 09.11.26 |
|